The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

200 SOUTH BISCAYNE BOULEVARD, SUITE 2500, MIAMI, FL 33131-5341, USA
Tel:
Work +1 305 423 8500
Fax:
Fax +1 305 437 8131
Web:
www.dlapiper.com

Joshua Kaye

Tel:
Work +1 305 423 8521
Email:
Web:
www.dlapiper.com/en/us/people/k/kaye-joshua/
DLA Piper LLP (US)

Work Department

Healthcare; Corporate

Position

Partner; Managing Partner DLA Piper's Miami Office; Chair of DLA Piper's US Healthcare Sector

Career

Joshua Kaye concentrates his practice in healthcare mergers and acquisitions and the development of innovative business models within the healthcare industry.

Joshua advises clients in all aspects of federal and state healthcare regulatory matters, including anti-kickback, self referral laws, state licensure, Corporate Practice of Medicine and Dentistry, Certificate of Need, insurance laws and HIPAA

Education

J.D., University of Miami School of Law; B.A., University of Florida


United States: Industry focus

Healthcare: service providers

Within: Healthcare: service providers

The healthcare team at DLA Piper LLP (US) is 'strong in regulatory compliance and all kinds of transactional work', while also offering dispute resolution and data privacy advice. Miami-based practice lead Joshua Kaye, who delivers 'exceptional service, quality of work and attention to detail', assisted Somos Innovation on the establishment of a Medicaid-focused, value-based care system in New York together with Evolent, while well-regarded Philadelphia litigator Brian Benjet advised BioMatrix Specialty Pharmacy and its affiliates on a fraud claim from Highmark under the Racketeer Influenced and Corrupt Organizations Act. Austin partner Karen Nelson - who has 'deep experience and a practical approach' - successfully represented a hospital and health system in its attempt to prove non-compliance of external auditors with the procedural requirements during the client's audit investigation. Tom Califano, who is based in New York, specialises in representing healthcare companies in Chapter 11 proceedings.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to